| ACC | American College of Cardiology |
| ADA | American Diabetes Association |
| AGA | American Gastroenterology Association |
| AHA | American Heart Association |
| AI | Artificial intelligence |
| ACEi | Angiotensin converting enzyme inhibitor |
| ARB | Angiotensin receptor blocker |
| ASO | Antisense Oligonucleotides |
| ANGPTL3 | Angiopoietin-like 3 |
| ASCVD | Atherosclerotic cardiovascular disease |
| CAD | Coronary artery disease |
| CETP | Cholesteryl ester transfer protein |
| CKM | Cardiovascular-kidney-metabolic syndrome |
| CVD | Cardiovascular disease |
| CKD | Chronic kidney disease |
| EASD | European Association for the Study of Diabetes |
| ESC | European Society of Cardiology |
| GLP1-RA | Glucagon-like peptide-1 receptor agonists |
| HFMREF | Heart failure with mildly reduced ejection fraction |
| HFPEF | Heart failure with preserved ejection fraction |
| HFREF | Heart failure with reduced ejection fraction |
| KDIGO | Kidney Disease: Improving Global Outcomes |
| KDOQI | National Kidney Foundation Kidney Disease Outcomes Quality Initiative |
| LDL | Low density lipoprotein |
| MACE | Major adverse cardiovascular events |
| MASLD | Metabolic dysfunction-associated steatotic liver disease |
| MASH | Metabolic dysfunction associated steatohepatitis |
| NAFLD | Nonalcoholic fatty liver disease |
| NASH | Nonalcoholic steatohepatitis |
| PCSK9 | Proprotein convertase subtilisin–kexin type 9 |
| RAS | Renin angiotensin system |
| SGLT2i | Sodium-glucose cotransporter 2 inhibitors |
| TRβ | Thyroid receptor beta |